CORDIS
EU research results

CORDIS

English EN
Immune DIREcted and Cancer-selective immunoTherapy

Immune DIREcted and Cancer-selective immunoTherapy

Objective

I-DireCT is a European Industrial Doctorate (EID) training network designed to provide training and carry out breakthrough research on the rapidly expanding and high impact field of cancer immunotherapy in a carefully integrated academic and inter-sectoral programme. Hereby, we aim to develop next-generation immunotherapeutics and deliver a set of early stage researchers uniquely qualified for a career in academia and/or industry.

Current immunomodulatory antibodies that target pivotal immune checkpoints have revolutionized the field of oncology. However, off-tumor activity limits their application. The objective of I-Direct is to address this issue by 1. developing innovative bispecific antibodies and immunocytokines with tumor-restricted immunostimulatory effects and 2. developing optimized delivery systems to ensure optimal timed release of bio-active drug. Hereto, I-DireCT combines state-of-the-art industrial design of nanotech-based drug formulations with innovative academic and industrial immunotherapeutic concepts into the next-generation of cancer immunotherapeutics.

At the core of I-DireCT is its training objective to offer a cutting-edge multidisciplinary training programme that will enable outstanding young scientists to generate breakthrough ideas and assume leading positions in academia and industry. This training programme includes an array of disciplines, ranging from biomedical sciences (e.g. immunology, antibody engineering) and physical sciences (e.g. chemistry, material science) to drug design & development.

Industrial partners are central to the programme and provide pivotal inter-sectoral expertise on how to translate scientific discoveries into commercial reality, with each ESR being appointed at an inter-sectoral partner for 18 months, as well as through additional secondments. Further, I-Direct will enable long-term multi-disciplinary research and fosters bilateral co-operations between academia and industry.
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

ACADEMISCH ZIEKENHUIS GRONINGEN

Address

Hanzeplein 1
9713 Gz Groningen

Netherlands

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 929 669,58

Participants (4)

Sort alphabetically

Sort by EU Contribution

Expand all

UNIVERSITAETSKLINIKUM WUERZBURG - KLINIKUM DER BAYERISCHEN JULIUS-MAXIMILIANS-UNIVERSITAT

Germany

EU Contribution

€ 379 182,60

INOCURE SRO

Czechia

EU Contribution

€ 587 178,90

Surflay Nanotec GmbH

Germany

EU Contribution

€ 505 576,80

KAHR MEDICAL LTD

Israel

EU Contribution

€ 131 750,46

Project information

Grant agreement ID: 813871

Status

Ongoing project

  • Start date

    1 January 2019

  • End date

    31 December 2022

Funded under:

H2020-EU.1.3.1.

  • Overall budget:

    € 2 533 358,34

  • EU contribution

    € 2 533 358,34

Coordinated by:

ACADEMISCH ZIEKENHUIS GRONINGEN

Netherlands